TAMPA, FL and SEOUL, SOUTH KOREA--(Marketwire - April 23, 2008) - Stem Cell Therapy International, Inc. (OTCBB: SCII) In a prior press release dated March 18, 2008, Stem Cell Therapy International, Inc. announced that it had entered into a Definitive Acquisition Agreement with Histostem, Co., Ltd., a substantial Korean stem cell and umbilical cord blood bank company. The definitive agreement called for closing of the acquisition by April 30, 2008. At this time the parties have decided to jointly announce that Stem Cell Therapy International and Histostem, Co., Ltd., will continue discussions with the various funding sources and extend the proposed closing date past April 30 until funding options can be evaluated and the best option selected. In their mutual agreement to extend the closing date both Stem Cell Therapy International and Histostem, Co., Ltd., reaffirmed their intention to close the merger as soon as a decision can be made on how to best fund the combined entities. The amendment also made other changes in the merger terms.
